Targeted Therapy in Pediatric Langerhans Cell Histiocytosis: Describing a Novel Strategy to Minimize Long‐Term Exposure While Maintaining Efficacy
Our data suggest that trametinib is a safe and effective therapy for pediatric LCH with broad efficacy and tolerability. However, prospective studies are needed to confirm these findings and refine targeted treatment protocols.
Authors
- Natalia Wojciechowska (ORCID: https://orcid.org/0009-0007-1215-0523)
- Maranda Diaz
- Alexandra E. Richards (ORCID: https://orcid.org/0000-0003-0651-4187)
- Kelly Vallance (ORCID: https://orcid.org/0000-0003-4185-921X)
- Anish Ray (ORCID: https://orcid.org/0000-0002-6349-1869)
- Chelsee Greer
- Aly Anthony
Institutions
- Texas Christian University (US)
- Cook Children's Medical Center (US)
Publication Details
- Journal
- Pediatric Blood & Cancer
- Published
- 2025-08-31
- DOI
- https://doi.org/10.1002/pbc.32016
- Citations
- 1
- Primary Topic
- Histiocytic Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.16